News Releases

Deborah Armstrong, MD, joins eviti Medical Advisory Board

Home Home > Homepage > Deborah Armstrong, MD, joins eviti Medical Advisory Board
| August 17, 2012 |

eviti, Inc., an independent, third-party expert with nearly a decade of experience supporting oncology treatment decisions and patient care, announced today that Dr. Deborah K. Armstrong joins 13 other expert oncology specialists who advise eviti’s professional staff on new cancer treatments and evolving standards of care within their specialties.

Dr. Armstrong is an expert in genetic screening and treatment of breast cancer, ovarian cancer and other gynecologic malignancies. Dr. Armstrong directs the Johns Hopkins Breast and Ovarian Cancer Screening Service, a genetic counseling service that identifies and counsels women at risk for cancer and examines new strategies for cancer prevention.

“With her extensive background, and involvement in the Gynecologic Oncology Group, National Comprehensive Cancer Network, National Cancer Institute, and her leadership in clinical trials conducted throughout the nation, Dr. Armstrong brings a wealth of knowledge concerning women’s malignancies,” said Dr. Arlene Forastiere, SVP, Medical Affairs and Medical Advisory Board Chairwoman at eviti, Inc.

Dr. Armstrong received her medical degree from George Washington University School of Medicine; and she completed a fellowship in medical oncology at the Johns Hopkins Oncology Center. She is an Associate Professor of Oncology at the Johns Hopkins University School of Medicine and Comprehensive Cancer Center.

About eviti

eviti, Inc. is a leading health information technology and clinical decision-support company delivering solutions to improve the quality of cancer care and reduce its cost. eviti represents the culmination of almost a decade of experience providing oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start.

eviti’s growing national prominence is evidenced by the 5,100+ oncologists already registered to use the eviti platform. eviti’s independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind, meticulously compiled from the world’s leading sources. eviti’s treatment knowledge base and patent-pending decision-support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient’s insurance plan language at the moment of prescribing. This transparent approach streamlines workflow and reimbursement, reduces variability in clinical care, and results in cost efficiencies. eviti allows the best cancer care to be available everywhere. For more information, visit www.eviti.com.